ODN/Pam2 - Pulmotect
Alternative Names: ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042Latest Information Update: 16 May 2025
At a glance
- Originator Pulmotect
- Developer Cancer Prevention & Research Institute of Texas; National Heart, Lung and Blood Institute; Pulmotect
- Class Antineoplastics; Antisense oligonucleotides; Antivirals; Lipopeptides
- Mechanism of Action Toll-like receptor 2 agonists; Toll-like receptor 6 agonists; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease; COVID 2019 infections; Lung disorders
- No development reported Haematological malignancies; Pneumocystis pneumonia
Most Recent Events
- 24 Apr 2025 Phase-II clinical trials in Lung disorders (Treatment-experienced) in USA (Inhalation) (NCT06665100)
- 30 Oct 2024 Pulmotect plans a phase II trial in Lung disorders (Treatment-experienced) in USA (Inhalation) in October 2025 (NCT06665100)
- 16 Oct 2024 Pharmacodynamics data from a preclinical trial in Lung disorders presented at the IDWeek 2024 (IDW-2024)